ilson's Disease (WD) is a metabolic disorder resulting from biallelic mutations in the ATP7B gene on chromosome 13 1,2,3 of autosomal recessive inheritance 3 , characterized by the toxic accumulation of this element in the liver, córnea, and central nervous system 4 .
The incidence of these mutations in newborns was estimated at 1:7,000 in Sardinia, Italy 5 and 1.7:100,000 in the Republic of Ireland 6 , in contrast, the prevalence of the disease has been estimated to be between 1:250,000 and 1:300,000 in Sweden and between 1:30,000 and 1:40,000 in other populations 7 .
Copper is an essential cofactor for several enzymes 8 and is present in foodstuffs such as seafood, pulses, and nuts 9 . Its metabolism is dependent on the ATP7B gene, which is responsible for encoding ceruloplasmin, and on the ATPase, which incorporates it into the bile and allows its exteriorization with the feces 10,11 .
Due to the absence of these mechanisms, copper accumulates in the liver until it spills over into the bloodstream. High levels of cupremia cause disruption of the blood-brain barrier and deposition with a cytotoxic effect in the striatum, globus pallidus, locus coeruleus, substantia nigra, and cerebral cortex 4,12 .
A 31-year-old male, mixed race, bricklayer, residing in Paraisópolis, Minas Gerais State, Brazil. History of alcoholism and drug use. Diagnosis of previous unspecified mood disorder and using Fluoxetine 40mg/day. No other relevant environmental exposures were reported. Report of a male adult family member diagnosed with liver failure of unknown etiology.
Magnetic Resonance Imaging (MRI) of the brain on December 1st, 2021, showed involvement of the putamen, associated with hemosiderin residue, and crus posterius bilaterally, in addition to the midbrain and pons, without restriction to diffusion (images 1A-1D), and an extra-axial parietal left paramedian contrastenhanced lesion suggestive of meningioma (images 1E-1F). On December 3rd, 2021, the patient suffered the first generalized clonic tonic seizure while sleeping, and in a follow-up visit on December 21st, he started to use Levetiracetam orally.
He was diagnosed with Covid 19 on February 3rd, 2022, with a mild evolution without the need for ventilatory support or complications. The wife noted that the development of the disease was accentuated after the infection. From February 9th, he appeared to have speech and gait disturbance, difficulty mobilizing the right hand, and urinary incontinence. During outpatient follow-up, a new MRI of the brain was requested on April 1st, 2022, which denoted better characterization of foci of signal alteration in cerebellar peduncles (images 2).
On June 2022, he had moderate dysarthria, hypomimia, right-hand flexor dystonia, tetraparesis, bradykinesia, and postural instability, but without rigid or resting tremors.
The specific treatment was started on May 2022 with pyridoxine chlorhydrate 50 mg daily and zinc sulfate heptahydrate 4 mg/mL 15mL three times a day orally. Due to the cost of the drug, the patient delayed starting penicillamine.
Incipient neurological symptoms are subtle and nonspecific, such as difficulty concentrating and motor coordination and handwriting changes (for example, micrograph) [13][14][15][16][17][18][19] and begin on average between 20 and 40 years [20][21][22] . As it progresses, more prominent symptoms appear, whose order of incidence is dysarthria (57.6%), dystonia (42.4%), abnormal gait (37.8%), tremor (36.2%), parkinsonism (17.3%), choreoathetosis (15.3%) and convulsion (4.7%) 16,17 . Neurological impairment occurs about a decade after liver failure and, therefore, signs of advanced disease 23 . Cognitive impairment is considered rare and was reported by Machado, Chien, Deguti, et al. ( 2006) 16 in 4.2% of cases.
Given the heterogeneity of clinical manifestations, the neurological phenotype of WD can be grouped for didactic purposes into dystonic, pseudosclerotic, parkinsonian, and hyperkinetic subtypes 4 . The patient discussed in this study had a predominance of the dystonic subtype manifested by multifocal dystonia affecting both the risorius muscle (sardonic laughter) and the flexor muscles of the right hand fingers. As reported by Lorincz (2010) 24 , bilateral putaminal lesions were found on an MRI of the brain.
Dysarthria can result from any condition that damages the motor control structures necessary for speech production, such as cranial nerves IX, X, XII, cerebellum, and basal ganglia 12 . In this case, it was noted evident bilateral impairment of the basal ganglia.
Seizures are not uncommon and are reported variably in 4.7% 16,17 to 14.5% 25 of WD cases. The patient in question presented, at the initial manifestation, a single episode of generalized tonic-clonic seizure without recurrence.
We also detected the presence of brownish Kayser Fleischer rings, more evident in the lower region of the iris bilaterally. Such a semiological sign is due to copper deposition in the Descemet's membrane of the cornea 26 and is present in approximately 100% of neuropsychiatric WD cases 10 .
Psychiatric symptoms are reported by about 30% to 60% of individuals affected by WD 26 . In this case, the disorder for which the patient had been using Fluoxetine was not specified. However, the familiar states that at the time of initiation of therapy, he had a depressive mood, anhedonia, and anxiety.
It is possible that such symptoms were already an incipient manifestation of central nervous system involvement.
Cognitive impairment is initially mild and recognized only by family members. It is categorized into frontal lobe syndrome, which involves impulsivity, promiscuity, apathy, hypotenacity, impaired social judgment, planning dysfunction, and emotional lability, and subcortical dementia characterized by slowed thinking amnesia, and executive dysfunction, but without aphasia, apraxia, or agnosia 10 . In this case, it was impossible to attribute a clinical syndrome related to the metabolic disorder, given the history of alcoholism and use of narcotics.
IV.
This case report represents the importance of a detailed neurological clinical evaluation and the association of findings with Imaging and laboratory workup. It is a rare disease whose epidemiology in Brazil lacks data, and complementary tests have reduced specificity.


No potential conflict of interest was reported by the authors.
Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson's Disease Rating Scale. BMC Neurol 2018. 18 p. 34.
Neurological manifestations in Wilson's disease: report of 119 cases. Mov. Disord 2006. 21 p. .
Determination of the frequencies of ten allelic variants of the Wilson disease gene (ATP7B), in pooled DNA samples. Eur. J. Hum. Genet 2000. 8 p. .
American association for study of liver diseases (AASLD). Hepatology 2008. 47 p. . (Diagnosis and treatment of Wilson's disease: an update)
Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin. J. Hepatol 1997. 27 p. .
Molecular characterization of Wilson disease in the Sardinian population-evidence of a founder effect. Hum. Mutat 1999. 14 p. .
Doença de Menkes: relato de um caso raro na Amazônia. Brazilian Journal of Health Review 2023. 6 (1) p. .
Prognostic significance of neurologic examination findings in Wilson disease. Park. Relat. Disord 2011. 17 p. .
Neurological Manifestations of Wilson's Disease: Pathophysiology and Localization of Each Component. Cureus 2020. 12 (11) p. 11509.
Wilson's disease. The presenting symptoms. Arch. Dis. Child 1962. 37 p. .
Mielopathy related to copper deficiency after bariatric surgery: case report Mielopatia relacionada à deficiência de cobre após cirurgia bariátrica: relato de caso. Brazilian Journal of Health Review 2021. 4 (6) p. .
Spectrum of epilepsy in Wilson's disease with electroencephalographic, MR imaging and pathological correlates. J Neurol Sci 2010. 291 p. .
An epidemiological study of Wilson's disease in the Republic of Ireland. Neurosurgery & Psychiatry 1993. 56 (3) p. . (Journal of Neurology)
Neurologic Wilson's disease. Ann N Y Acad Sci 2010. 1184. p. .
Wilson disease and related copper disorders. Handbook of Clinical Neurology 2018. 147 p. .
The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet 1993. 5 p. .
Pathophysiology and clinical features of Wilson disease. Metabolic brain disease 2004. 19 p. .
Wilson's disease: A master of disguise. Parkinsonism & Related Disorders 2019. 59 p. .
The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet 1993. 5 p. .
Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. Arch. Neurol 1987. 44 p. .
Presenting symptoms and natural history of Wilson disease. Eur. J. Pediatr 1987. 146 p. .
Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J. Neurol 1991. 238 p. .
Clinical features of Wilson disease. Annals of Translational Medicine 2019. 7 (2) p. 61.
Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Ann. N. Y. Acad. Sci 2004. 1012 p. .
An overview and update of ATP7A mutations leading to Menkes disease and occipital horn syndrome. Hum. Mutat 2013. 34 p. .